natgillin/translations-raw huggingface dataset:
Do not drive or perform dangerous activities until you are certain Sixmo does not reduce your ability in such activities.
Ne vozite in ne opravljajte nevarnih opravil, dokler niste prepričani, da zdravilo Sixmo ne zmanjšuje vaše sposobnosti za opravljanje teh aktivnosti.
This may be related to existing reduced liver function and ongoing injecting drug use.
To je lahko povezano z obstoječim delovanjem jeter in sočasno uporabo drog, ki se injicirajo.
• lack of a white blood cell type called neutrophils
• pomanjkanje belih krvničk, ki jih imenujemo nevtrofilci,
In the post-marketing setting, 2 cases were reported where Sixmo implants had locally migrated from the insertion site.
V obdobju po začetku trženja so poročali o 2 primerih, kjer so se implantati Sixmo lokalno premaknili z mesta vstavitve.
In the majority of patients, heroin was the primary opioid of use.
Pri večini bolnikov je bil primarni uporabljeni opioid heroin.
Abuse of buprenorphine poses a risk of overdose and death.
Zloraba buprenorfina predstavlja tveganje prevelikega odmerjanja in smrti.
You must be on a stable buprenorphine dose of between 2 to 8 mg per day, given under the tongue.
Morate prejemati stabilen odmerek buprenorfina 2 do 8 mg na dan, ki se daje pod jezik.
Step 18: Disposal of Sixmo implants should be in accordance with local requirements as it contains buprenorphine.
18. korak: Implantate Sixmo je treba zavreči v skladu z lokalnimi zahtevami, saj implantat vsebuje buprenorfin.
Patients who have contraindications for MRI.
Bolniki s kontraindikacijami za MRI
Do not blot or wipe away.
Ne pivnajte ali obrišite.
Suitable methods for location include ultrasound with a high frequency linear array transducer (10 MHz or greater) or, in case ultrasound is not successful, magnetic resonance imaging (MRI).
Med ustrezne metode za iskanje položaja spadajo ultrazvok z visokofrekvenčnim pretvornikom z linearnim nizom (10 MHz ali več) ali, če ultrazvok ni uspešen, magnetnoresonančno slikanje (MRI).
The closer the implants lie to each other at the time of insertion, the more easily they can be removed.
Manjši ko je razmik med implantati po vstavitvi, lažje jih bo odstraniti.
The reduced level of alertness can make driving and using machines hazardous (see section 4.7).
Zaradi zmanjšane pozornosti lahko vožnja in upravljanje s stroji postaneta nevarna (glejte poglavje 4.7).
What Sixmo is and what it is used for What you need to know before you use Sixmo How to use Sixmo
Kaj je zdravilo Sixmo in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Sixmo Kako uporabljati zdravilo Sixmo
Sixmo implants are not radiopaque and cannot be seen by X-ray or CT scan.
Implantati Sixmo so prepustni za rentgenske žarke in jih pri rentgenskem ali CT-slikanju ni mogoče videti.
It must be handled with adequate security and accountability for proper disposal in accordance with local requirements.
Z njimi je treba ravnati na ustrezno varen in odgovoren način ter jih pravilno zavreči v skladu z lokalnimi predpisi.
Before engaging driving or operating hazardous machinery patients should be reasonably certain that Sixmo does not adversely affect their ability to engage in such activities.
Preden se lotijo vožnje ali upravljanja strojev, morajo biti bolniki razumno prepričani, da zdravilo Sixmo ne vpliva negativno na njihovo sposobnost opravljanja takih aktivnosti.
Patients not adequately treated with the 4 implant dose could receive a fifth implant.
Bolniki, ki niso bili ustrezno zdravljeni z odmerkom 4 implantatov, so lahko prejeli peti implantat.
The effect of hepatic impairment on the pharmacokinetics of Sixmo has not been studied.
Učinka okvare jeter na farmakokinetiko zdravila Sixmo niso preučevali.
Step 10: Verify the presence of each implant (26.5 mm in length) by palpation of the patient's arm immediately after the insertion, as shown in Figure 14.
10. korak: Potrdite prisotnost vsakega implantata (dolžine 26,5 mm) tako, da potipate bolnikovo roko tik za rezom, kot prikazuje slika 14.
• Your doctor should examine the insertion site for infections and wound problems: one week after implant insertion and at least once a month thereafter
• Zdravnik mora pregledati mesto vstavitve glede okužb in težav z rano: en teden po vstavitvi implantata in zatem vsaj enkrat na mesec.
There was a greater occurrence of resorptions and an increase in the number of stillbirths.
Pojavnost resorpcije je bila večja, prav tako je bilo večje število mrtvoskotenih mladičev.
Literature data indicated no genotoxic properties of buprenorphine.
Podatki iz literature ne navajajo genotoksičnih lastnosti buprenorfina.
• 100×100 mm sterile gauze
• sterilna gaza 100 × 100 mm,
• excessive sleepiness
• prekomerna zaspanost,
• slow heartbeat, abnormal heart rhythm that starts in the atrial chambers of the heart
• počasen srčni utrip, nenormalen srčni ritem, ki se začne v srčnih preddvorih (atrijih),
PHARMACEUTICAL FORM AND CONTENTS 1 implant
FARMACEVTSKA OBLIKA IN VSEBINA 1 implantat
Due to the inflexibility with regard to dose increases and to the increased dose requirements during pregnancy, Sixmo is not considered to be an optimal treatment choice for pregnant women, therefore treatment with Sixmo should not be started in pregnant women.
Zaradi neprilagodljivosti v zvezi s povečevanjem odmerka in zaradi potreb po večjem odmerku med nosečnostjo, zdravilo Sixmo ne velja za optimalno izbiro zdravljenja pri nosečnicah, zato zdravljenja z zdravilom Sixmo ni dovoljeno uvesti pri nosečnicah.
Clinical studies of Sixmo did not include patients over 65 years and, therefore, the use of the product in this population is not recommended.
Klinične študije zdravila Sixmo niso vključevale bolnikov, starejših od 65 let, zato uporaba tega zdravila pri tej populaciji ni priporočljiva.
The safety and efficacy of Sixmo was investigated in 3 double-blind Phase 3 clinical studies in which a total of 309 patients were treated with Sixmo for up to 6 months (1 implant cycle).
Klinična učinkovitost in varnost zdravila Sixmo Varnost in učinkovitost zdravila Sixmo so preučevali v 3 dvojno slepih kliničnih študijah 3. faze, kjer so skupno 309 bolnikov z zdravilom Sixmo zdravili do 6 mesecev (1 cikel implantatov).
Before inserting Sixmo, your doctor will give you a local anaesthetic to numb the area.
Preden bo zdravnik vstavil zdravilo Sixmo, vam bo dal lokalni anestetik, da bo omrtvičil območje.
There is no suspicion of carcinogenicity based on the clinical use of buprenorphine.
Sum na kancerogenost na podlagi klinične uporabe buprenorfina ne obstaja.
Buprenorphine may reduce the ability to drive and use machines; especially during the first 24 to 48 hours up to one week following implant insertion.
Vpliv na sposobnost upravljanja vozil in strojev Buprenorfin lahko poslabša sposobnost upravljanja vozil in strojev, zlasti v prvih 24 do 48 urah ter do enega tedna po vstavitvi implantata.
Patients may experience somnolence, especially in the first week following insertion of the implants and should be cautioned in this respect (see section 4.7).
Pri bolnikih se lahko pojavi zaspanost, zlasti prvi teden po vstavitvi implantatov, na kar je bolnike treba opozoriti (glejte poglavje 4.7).
Excessive palpation shortly after insertion of the implants may increase the chance of infection.
Prekomerna palpacija takoj po vstavitvi implantatov lahko poveča možnost za okužbo.
Especially, inform your doctor during Sixmo treatment before using:
Zlasti obvestite zdravnika med uporabo zdravila Sixmo, preden vzamete:
MOLTeNI-2019-01 - A prospective, observational (non-interventional), postauthorisation safety cohort study to evaluate the incidence of the breakages and insertion/removal complications of buprenorphine implants (Sixmo) in the routine clinical care
MOLTeNI-2019-01 - Prospektivna, opazovalna (neintervencijska) kohortna študija v obdobju trženja za ocenitev incidence zloma in zapletov z vstavitvijo/odstranitvijo implantatov buprenorfina (Sixmo) v rutinski klinični negi
The formation of norbuprenorphine was initially found to be performed by CYP3A4; subsequent studies also demonstrated the involvement of CYP2C8.
Najprej je bilo ugotovljeno, da norbuprenorfin nastaja prek citokroma CYP3A4, nadaljnje študije pa so pokazale tudi vpletenost citokroma CYP2C8.
• have acute alcoholism or alcohol delirium caused by withdrawal from alcohol
• če imate akutni alkoholizem ali alkoholni delirij zaradi odtegnitve od alkohola;
Study PRO-806 included an open-label comparator arm with sublingual buprenorphine (12 to 16 mg/day).
Študija PRO-806 je vključevala odprti primerjalni krak s podjezičnim buprenorfinom (12 do 16 mg/dan).
The efficacy and safety of buprenorphine in elderly patients > 65 years has not been established.
Učinkovitost in varnost buprenorfina pri bolnikih, starejših od 65 let, nista bili dokazani.
Buprenorphine and its metabolites are excreted in human milk to such an extent that effects on the breastfed newborns/infants are likely.
Buprenorfin in njegovipresnovki se v materino mleko izločajo v tolikšnem obsegu, da je možen učinek na dojene novorojence/otroke.
• depression, euphoria
• depresija, evforija,
Implants should be removed under aseptic conditions, whereby the following equipment is needed:
Implantate je treba odstraniti v aseptičnih pogojih, potrebna pa je naslednja oprema:
A mass balance study of buprenorphine showed complete recovery of radiolabel in urine (30%) and faeces (69%) collected up to 11 days after dosing.
Izločanje Študija masnega ravnovesja buprenorfina je pokazala popolno izločenje radioaktivno označene spojine z urinom (30 %) in blatom (69 %), katerih vzorci so bili odvzeti do 11. dni po odmerjanju.
Because buprenorphine levels cannot be adjusted during Sixmo treatment, Sixmo is contraindicated in patients with severe hepatic impairment (Child-Pugh C) (sections 4.3, 4.4 and 5.2).
Ker ravni buprenorfina med zdravljenjem z zdravilom Sixmo ni mogoče prilagoditi, je zdravilo Sixmo kontrainidicirano pri bolnikih s hudo okvaro jeter (Child-Pugh C) (poglavja 4.3, 4.4 in 5.2).
Deaths have also been reported in association with concomitant administration of buprenorphine and other depressants such as alcohol or other opioids.
O smrtnih primerih so poročali tudi v povezavi s sočasno uporabo buprenorfina in drugih depresorjev, kot sta alkohol ali drugi opioidi.
Pups exposed to buprenorphine only during the prenatal period had a similar body weight compared with controls in the first 3 postnatal weeks.
Mladiči, ki so bili buprenorfinu izpostavljeni le v prenatalnem obdobju, so imeli v prvih 3 ponatalnih tednih telesno maso podobno kontrolni skupini.
Step 2: Clean the insertion site with an alcohol pad.
2. korak: Mesto vstavitve očistite z alkoholno blazinico.
• Opioid antagonists: naltrexone and nalmefene can block the pharmacological effects of buprenorphine.
• opioidnimi antagonisti: naltrekson in nalmefen lahko blokirata farmakološke učinke buprenorfina.
• 5 mL syringe with 25G×1.5" needle (0.5×38 mm)
• 5-ml brizga z iglo velikosti 25 G × 1,5 palca (0,5 × 38 mm),
After Sixmo implant insertion, an initial buprenorphine peak was observed and the median Tmax occurred at 12 hours after insertion.
Po vstavitvi implantata Sixmo je bil opažen začetni višek buprenorfina, z medianim Tmax 12 ur po vstavitvi.
• reopening of a closed wound
• vnovično odprtje zaprte rane,
The demonstration of efficacy relies primarily on study PRO-814, a randomized, double-blind and active-controlled Phase 3 study in adult patients who met DSM-IV-TR criteria for opioid dependence and who were clinically stabilised on sublingual buprenorphine.
Prikaz učinkovitosti temelji predvsem na študiji PRO-814, randomizirani, dvojno slepi in z aktivno kontrolo nadzorovani študiji 3. faze pri odraslih bolnikih, ki so izpolnjevali pogoje DSM-IV-TR glede odvisnosti od opioidov in so bili klinično stabilizirani s podjezičnim buprenorfinom.
• verapamil, diltiazem, amiodarone: medicines to treat high blood pressure and heart disorders
• verapamil, diltiazem, amiodaron: zdravila za zdravljenje visokega krvnega tlaka in srčnih bolezni;
Plasma concentrations of buprenorphine after insertion of Sixmo are highest during the first 24 to 48 hours.
Koncentracije buprenorfina v plazmi so po vstavitvi zdravila Sixmo najvišje v prvih 24 do 48 urah.
There are no prospective data with Sixmo beyond two treatment cycles, and there is no experience with inserting Sixmo implants into other sites of the arm, sites other than the upper arm or re-insertion into previously-used sites.
Ni prospektivnih podatkov o več kot dveh ciklih zdravljenja z zdravilom Sixmo, prav tako ni izkušenj z vstavljanjem implantatov Sixmo v druge dele roke (razen nadlakti) oziroma izkušenj s ponovno vstavitvijo v prej uporabljena mesta.
Improper removal carries risk of implant-site infection and implant breakage.
Neustrezno odstranjevanje prinaša tveganje za okužbo na mestu implantata in zlom implantata.
A number of cases of death due to respiratory depression have been reported while on buprenorphine, particularly when buprenorphine was used in combination with benzodiazepines (see section 4.5) or when buprenorphine was not used according to prescribing information.
Poročali so o številnih primerih s smrtnim izidom zaradi depresije dihanja med uporabo buprenorfina, zlasti pri uporabi buprenorfina skupaj z benzodiazepini (glejte poglavje 4.5) ali kadar se buprenorfin ni uporabljal v skladu z navodili glede predpisovanja.
• the patient experiences lack of efficacy, as evidenced by lasting withdrawal symptoms that require repeated management with sublingual buprenorphine
• v primeru premajhne učinkovitosti pri bolniku, na kar nakazujejo dolgotrajni odtegnitveni simptomi, ki zahtevajo ponavljajoče zdravljenje s podjezičnim buprenorfinom.
Step 17: After removal of all implants, clean the incision site.
17. korak: Ko odstranite vse implantate, očistite mesto reza.
• Patients who have contraindications for MRI should be not allowed to receive the implant.
• Bolniki s kontraindikacijami za MRI ne smejo prejeti implantata.
If opioid therapy is required as part of anaesthesia, patients should be continuously monitored in an anaesthesia care setting by persons not involved in the conduct of the surgical or diagnostic procedure.
Če je v sklopu anestezije potrebna terapija z opioidi, morajo bolnike v anestezijskem okolju stalno spremljati osebe, ki niso vključene v izvajanje kirurškega ali diagnostičnega postopka.
Do not drink alcohol during Sixmo treatment, as it increases the sedative effect.
Med uporabo zdravila Sixmo ne pijte alkohola, ker povečuje učinek sedacije.
Buprenorphine can cause fatal breathing problems in non-dependent people or children.
Buprenorfin lahko povzroči usodne težave z dihanjem osebah, ki niso odvisne, ali pri otrocih.
These adverse reactions are presented by MedDRA system organ class, preferred term, and frequency.
Ti neželeni učinki so razvrščeni po organskih sistemih MedDRA, po prednostnem izrazu in pogostnosti.
See “Driving and using machines”.
Glejte „Vpliv na sposobnost upravljanja vozil in strojev“.
The partial opioid agonist properties of buprenorphine may precipitate opioid withdrawal signs and symptoms in persons who are currently physically dependent on full opioid agonists - such as heroin, morphine, or methadone - before the effects of the full opioid agonist have subsided.
Buprenorfin zaradi svojih značilnosti delnega opioidnega agonista lahko povzroči odtegnitvene znake in simptome pri osebah, ki so trenutno fizično odvisne od polnih opioidnih agonistov, kot so heroin, morfin in metadon, še preden učinki polnega opioidnega agonista prenehajo.
• infection, such as viral infection (e.g. flu)
• okužba, kot je virusna okužba (npr. gripa),
Pharmacotherapeutic group: Other nervous system drugs, Drugs used in opioid dependence, ATC code: N07BC01
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: druga zdravila z delovanjem na živčevje, zdravila za zdravljenje odvisnosti z opioidi, oznaka ATC: N07BC01
In both studies adult patients with opioid dependence who were new entrants to buprenorphine treatment were treated over 24 weeks with 4 Sixmo or 4 placebo implants.
V obeh študijah so bili odrasli bolniki z odvisnostjo od opioidov, ki so bili na novo deležni zdravljenja z buprenorfinom, zdravljeni 24 tednov s 4 implantati zdravila Sixmo ali 4 implantati s placebom.
Uncommon, may affect up to 1 in 100 people
Občasni, pojavijo se lahko pri največ 1 od 100 bolnikov
Generally, concentrations were comparable to the trough buprenorphine concentration of 8 mg per day sublingual buprenorphine.
Na splošno so bile koncentracije primerljive z najnižjo koncentracijo buprenorfina, doseženo pri odmerku 8 mg na dan v obliki podjezičnega buprenorfina.
Generally, other buprenorphine treatments/formulations are considered more appropriate in this situation.
V tem primeru so na splošno ustreznejša druga zdravila/pripravki, ki vsebujejo buprenorfin.
• two X-plant clamps (vasectomy fixation clamps with 2.5 mm ring diameter)
• dve sponki X-plant (fiksacijske sponke za vazektomijo s premerom odprtine 2,5 mm),
Sixmo should be used only in patients who are opioid tolerant.
Zdravilo Sixmo smejo uporabljati le bolniki, ki nimajo intolerance na opioide.
Each Sixmo implant is packaged individually into a PET/LDPE/Alu/LDPE-peelable foil laminate sachet.
Vsak implantat zdravila Sixmo je pakiran posamično v laminirane vrečice iz folije PET/LDPE/Alu/LDPE.
Prior to initiating Sixmo therapy, the patient's medical and treatment history, including use of nonopioid psychoactive substances, needs to be reviewed, in order to ensure that Sixmo treatment can be safely initiated.
Pred uvedbo zdravljenja z zdravilom Sixmo je treba pregledati bolnikovo zgodovino zdravljenja, vključno z uporabo neopioidnih psihoaktivnih snovi, da zagotovite varno uvedbo zdravljenja z zdravilom Sixmo.
Table 1: Adverse reactions reported in clinical studies and from post-marketing data with Sixmo and/or reported with other buprenorphine product System organ class
Preglednica 1: Neželeni učinki, o katerih so poročali v kliničnih študijah in po začetku trženja zdravila Sixmo in/ali o katerih so poročali v povezavi z drugimi zdravili, ki vsebujejo buprenorfin Organski sistem
Do not force the implant beyond the end of the cannula with the obturator.
Implantata z mandrenom ne potiskajte preko konca kanile.
In faeces, almost all of the buprenorphine and norbuprenorphine were free (buprenorphine: 33% free and 5% conjugated; norbuprenorphine: 21% free and 2% conjugated).
V blatu sta bila skoraj ves buprenorfin in norbuprenorfi prosta (buprenorfin: 33 % prostega in 5 % konjugiranega; norbuprenorfin: 21 % prostega in 2 % konjugiranega).
Sublingual buprenorphine N=119
Podjezični buprenorfin n = 119
There should be at least 5 mm between the incision and the implant when the implant is properly positioned.
Med rezom in implantatom mora biti vsaj 5 mm prostora, če je implantat ustrezno nameščen.
The safety and efficacy of Sixmo in children under 18 years have not yet been established.
Varnost in učinkovitost zdravila Sixmo pri otrocih, starih manj kot 18 let, nista bili dokazani.
Do not use these medicines during Sixmo treatment as they can cause a sudden onset of prolonged, intense withdrawal symptoms.
Teh zdarvil med zdravljenjem z zdravilom Sixmo ne uporabljajte, saj lahko nenadoma sprožijo dolgotrajne, intenzivne odtegnitvene simptome;
They are removed by the doctor at the end of the sixth month.
Na koncu obdobja 6 mesecev jih zdravnik odstrani.
Alternatively, replacement implant(s) may be inserted in the contralateral arm.
Nadomestni(-e) implantat(-e) lahko vstavite tudi v nasprotno roko.
• vulvovaginal fungal infection
• vulvovaginalna glivična okužba,
• aprepitant: a medicine to prevent nausea and vomiting
• aprepitant: zdravilo za preprečevanje slabosti in bruhanja;
The opioid antagonist naloxone is a specific antidote to respiratory depression resulting from opioid overdose.
Opioidni antagonist nalokson je specifični antidot za depresijo dihanja, ki se pojavi zaradi prevelikega odmerjanja opioidov.
Higher than normal doses and repeated administration may be necessary.
Morda bodo potrebni večji odmerki kot običajno in večkratno dajanje.
• local anaesthetic, such as 1% lidocaine with adrenaline 1:100,000
• lokalni anestetik, kot je 1-% lidokain z adrenalinom 1 : 100.000,
Mark the insertion site with the surgical marker.
Mesto vstavitve označite s kirurškim markerjem.
In the case of non-palpable implants, removal should be performed under ultrasound guidance (following their localisation).
Če implantatov ni mogoče zatipati, je treba postopek odstranjevanja izvesti pod ultrazvočnim vodenjem (po njihovi lokalizaciji).
Due to the long half-life of buprenorphine, neonatal monitoring for several days should be considered at the end of pregnancy, to prevent the risk of respiratory depression or withdrawal syndrome in neonates.
Zaradi dolge razpolovne dobe buprenorfina je treba razmisliti o nekajdnevnem neonatalnem spremljanju ob koncu nosečnosti, da se prepreči tveganje za depresijo dihanja ali odtegnitveni sindrom pri novorojencih.
The most frequent non-implant adverse reactions in clinical studies with Sixmo were headache, constipation and insomnia.
Najpogostejši neželeni učinki, nepovezani z implantatom, v kliničnih študijah z zdravilom Sixmo so bili glavobol, zaprtost in nespečnost.
At steady state, a small decrease in buprenorphine concentrations was also recorded between week 4 and week 24.
V stanju dinamičnega ravnovesja je bilo manjše zmanjšanje koncentracije buprenorfina opaženo tudi med 4. in 24. tednom.
Patients requiring opioid therapy for analgesia may be treated with a high-affinity full opioid analgesic under the supervision of a healthcare professional, with particular attention to respiratory function.
Bolnike, pri katerih je za analgezijo potrebna terapija z opioidi, je dovoljeno zdraviti z visokoafinitetnimi polno opioidnimi analgetiki pod nadzorom zdravstvenega strokovnjaka, ki mora biti pozoren zlasti na respiratorno funkcijo.
Step 16: After removal of each implant, confirm that the entire 26.5 mm long implant has been removed by measuring its length.
16. korak: Ko odstranite vsak implantat, potrdite, da ste odstranili celoten 26,5-milimetrski implantat tako, da pomerite njegovo dolžino.
Note: Do not push the obturator.
Opomba: Mandrena ne potiskajte.
• small bleeds beneath the skin
• manjše krvavitve pod kožo,
Bring it to the inserting doctor to determine whether the full implant has been expelled.
Prinesite ga zdravniku, ki je opravil vstavitev, da oceni, ali se je iztisnil celoten implantat.
• The healthcare professional must carefully monitor the patient until the implant is replaced to evaluate for withdrawal or other clinical indicators suggesting that supplemental sublingual buprenorphine may be needed.
• Zdravstveni strokovnjak mora bolnika skrbno spremljati, dokler bolnik ne dobi drugega implantata, in ocenjevati odtegnitvene simptome ali druge klinične kazalnike, ki bi kazali na to, da bo treba uporabiti dodatni podjezični buprenorfin.
Using aseptic technique, place the sterile equipment on the sterile field of the instrument stand.
Z aseptično tehniko sterilno opremo postavite v sterilno polje na instrumentarsko mizico.
If you stop Sixmo treatment your doctor will monitor you for withdrawal symptoms.
Če zdravljenje z zdravilom Sixmo prekinete, vas bo zdravnik spremljal glede odtegnitvenih simptomov.
Renal elimination plays a relatively small role (approximately 30%) in the overall clearance of buprenorphine and buprenorphine plasma concentrations were not increased in patients with renal impairment.
Okvara ledvic Izločanje skozi ledvice igra relativno majhno vlogo (približno 30 %) pri celokupnem očistku buprenorfina, koncentracije buprenorfina v plazmi pa se pri bolnikih z okvaro ledvic niso povečale.
Although some patients may require occasional supplemental dosing with buprenorphine, patients should not be provided with prescriptions for sublingual buprenorphine-containing products for asneeded use.
Čeprav bodo nekateri bolniki občasno morda potrebovali dodatne odmerke buprenorfina, bolniki ne smejo prejeti receptov za podjezična zdravila, ki vsebujejo buprenorfin, za uporabo po potrebi.
If you have more Sixmo than you need
Če ste dobili večji odmerek zdravila Sixmo, kot bi smeli